Atika Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Atika Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8,750	Closed	-$1.48M	–	96
2017 Q2	$1.62M	Buy	8,750 +6,000	+218%	+$1.05M	0.57%	58
2017 Q1	$329K	Sell	2,750 -2,250	-45%	-$236K	0.16%	62
2016 Q4	$497K	Sell	5,000 -4,250	-46%	-$448K	0.3%	54
2016 Q3	$1.04M	Buy	+9,250	New	+$1.11M	0.42%	61
2016 Q1	–	Sell	-13,125	Closed	-$1.89M	–	67
2015 Q4	$1.89M	Buy	13,125 +3,750	+40%	+$488K	0.97%	38
2015 Q3	$969K	Hold	9,375	–	–	0.48%	47
2015 Q2	$1.53M	Buy	+9,375	New	+$1.59M	0.69%	50

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IPLA

Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Atika Capital Management's SIOX Position: Q3 2017 in Review

Atika Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 8,750 shares — an estimated $1.48M sold.

Atika Capital Management first reported a position in SIOX in Q2 2015 and held it in 7 quarters. The position peaked at $1.89M in Q4 2015. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

Atika Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Atika Capital Management sold 8,750 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $1.48M.
Atika Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 7 quarters.
Atika Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.89M in Q4 2015.
114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on Atika Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.